PHENTERMINE HYDROCHLORIDE IS INDICATED AS A SHORT-TERM (A FEW WEEKS) ADJUNCT IN A REGIMEN OF WEIGHT REDUCTION BASED ON EXERCISE, BEHAVIORAL MODIFICATION AND CALORIC RESTRICTION IN THE MANAGEMENT OF EXOGENOUS OBESITY FOR PATIENTS WITH AN INITIAL BODY MASS INDEX = 30 KG/M2, OR = 27 KG/M2 IN THE PRESENCE OF OTHER RISK FACTORS (E.G., HYPERTENSION, DIABETES, HYPERLIPIDEMIA).
THE USUAL ADULT DOSE IS ONE CAPSULE OR TABLET (37.5 MG) DAILY, ADMINISTERED BEFORE BREAKFAST OR 1-2 HOURS AFTER BREAKFAST. THE DOSAGE MAY BE ADJUSTED TO THE PATIENT'S NEED. FOR SOME PATIENTS 1/2 TABLET (18.75 MG) DAILY MAY BE ADEQUATE, WHILE IN SOME CASES IT MAY BE DESIRABLE TO GIVE 1/2 TABLET (18.75 MG) TWO TIMES A DAY.
LATE EVENING MEDICATION SHOULD BE AVOIDED BECAUSE OF THE POSSIBILITY OF RESULTING INSOMNIA.
PHENTERMINE IS NOT RECOMMENDED FOR USE IN PATIENTS SIXTEEN (16) YEARS OF AGE AND UNDER.